Parow Entheobiosciences
Focused-spectrum psychedelics for mental health
Fully integrated, pre-clinical stage biotechnology company developing therapeutics for accessible treatment of psychiatric diseases
Mission
Develop better and accessible treatments for psychiatric disorders derived from under-researched entheogenic compounds
Focus
Bring our lead compound, a psilocybin-synergistic tryptamine combination, that has shown pre-clinical evidence of better and longer-lasting efficacy, into clinical proof of concept in obsessive- compulsive disorder
Science
Leverage the neuroplastic effects of entheogen-derived molecules for psychiatric therapies
Dosing schedules and formulations that avoid the hallucinogenic effects
Microbial biomanufacturing platform
Achievements from discovery to the clinic
DISCOVERY
Major research correlating mushrooms, tryptamines and psychedelic experience
World-first, cell-based 5- MeO-DMT
PRE-CLINICAL
Demonstrated superiority of P601 over synthetic psilocybin including duration and efficacy in disease models and increased synaptic plasticity (biomarkers, IEG, behavioral phenotyping and metabolomics)
IP
Strong patent position for key indications and broad, defensible bio- manufacturing IP
8 filed patents
SCREENING
AI-based phenotypic screening in 2 non-human models
In-house fully equipped zebrafish laboratory for high throughput screening
LC-MS/MS, UHPLC-MS, MS- Flash, cell culture laboratory
MANUFACTURING
cGMP level biomass production facility
Proprietary extraction, purification and fractionation technology
Microbial manufacturing using novel method and technology
CLINICAL
OCD trial preparation with top-tier advisors
Health economics/RWE capabilities for future reimbursement strategies
